Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer

BACKGROUND AND OBJECTIVE: Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small-cell lung cancer. Trilaciclib is a substrate and time-dependent inhibitor of cytochrome P450 3A4 and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chao, Horton, Janet K., Sale, Mark, Curd, Laura, Goti, Vineet, Tao, Wenli, Beelen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338108/
https://www.ncbi.nlm.nih.gov/pubmed/35842567
http://dx.doi.org/10.1007/s40261-022-01179-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338108/
https://www.ncbi.nlm.nih.gov/pubmed/35842567
http://dx.doi.org/10.1007/s40261-022-01179-x

Ejemplares similares